World’s pharmaceutical development and manufacturing base moving to India
20 August 2013
The India Brand Equity Foundation (IBEF) predicts that the Indian pharmaceutical market will progress from the major generics producer to a world centre for development and production of patented products.
Over the last three years exports of pharmaceuticals (largely generics) have grown at over 21.5% (CAGR) and now accounts for over US$13bn in annual sales. Highlighting India’s dominance, nearly 40% of Abbreviated New Drug Applications (ANDA) received by the FDA in 2012 were from India, with a further 87 confirmed and another 25 already received between January and June 2013.
This huge growth in generics production has seen the country become a hotbed of manufacturing innovation — India has over 3000 DMFs registered with the US FDA — which coupled with increased investments in R&D, says IBEF, means India is now ready to challenge traditional big pharma and start producing more patented products.
A natural evolution of the success of the generics market has been the rise in supergenerics across India where much R&D spend is currently being invested (eg Lincoln Pharma’s patent for NDDS).
With the world’s pharmaceutical development manufacturing base moving to India — there are 546 US FDA approved company sites (second only to the US), 23 companies holding 1100 authorisations with UK's MHRA, and 166 companies with CEPs (Certificates of Suitability) from EDQM — coupled with the rise in supergenerics, the country’s next natural step is to use its world leading development expertise in the creation of new chemical entities.
Recognising this opportunity, the Government of India is putting in place supportive initiatives with the goal of cementing the country’s position as the ‘pharmacy of the world’ and creating a global innovation hub.
With generics predicted to rise to 35% of global pharmaceutical market value by 2016 (some $400bn+), and with an annual growth rate of 27% amongst Indian generics exports (comparing very favourably with the global average of 10%) the Government and Pharmexcil are forecasting much of this revenue will be reinvested across the country in new research, leading to a steady pipeline of future drug targets.
In support of this, the Indian Government has committed to three schemes including a major multi-billion dollar initiative with 50% public funding through a public-private partnership (PPP) model to harness India’s innovation capability.
In addition, the Government has also:
Already this year, India’s Dr Reddy’s, Lupin Labs, Sun Pharma, Ranbaxy and Cipla have invested over $500million in R&D, which is allowing increased innovation in manufacturing processes and will ultimately help to lower the cost of medicines production.
“India, termed as the Pharmacy of the World, has a basket of wide spectrum of generics that are second to none in terms of quality. The industry is on the track to expand its reach to newer markets, which makes it equally critical for the Indian pharmaceutical industry to keep its focus on quality, affordability and accessibility of medical solutions for the global pharma market.
The country’s success in generics manufacturing is helping to keep our industry at the forefront of innovation and over the next few years we are lending our support to the R&D effort across the country so that we are leading in generics production and even developing new drugs out of India” said Mr Rajeev Kher, Additional Secretary, Department of Commerce, Ministry of Commerce and Industry, Government of India.
“Being a world leader in generics, India already has a huge presence in the highly regulated markets in terms of pharma exports. Almost two thirds of Indian generic exports are to the highly regulated markets (eg the US and Europe), which speaks volumes about the quality of Indian medicines. The Government of India is supporting Brand India Pharma campaign to reiterate that the Indian pharma market offers credible, affordable and sustainable healthcare solutions,” said Dr P V Appaji, Director General, Pharmexcil.